CJC-1295 (without DAC) vs Oxandrolone
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Oxandrolone work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Oxandrolone
Weight 3,367.97 Da 306.44 Da
Half-life 30 minutes - 2 hours ~9-10 hours
Chain 30 amino acids —
Type GHRH analog 17-alpha-alkylated anabolic-androgenic steroid (C19H30O3)
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Oxandrolone
01 Promotes lean muscle mass gains with minimal water retention
02 Supports recovery of lost body weight following surgery, trauma, or chronic illness
03 Reduces bone pain associated with osteoporosis and improves bone mineral density
04 Does not aromatize to estrogen, avoiding estrogen-related side effects
05 Well-studied safety profile in women, children, and burn patients
06 Enhances nitrogen retention and protein synthesis during caloric deficit
07 Attenuates glucocorticoid-induced catabolism in post-surgical and burn patients
08 Lower androgenic potency compared to most oral anabolic steroids
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Oxandrolone
20-50 mg/day (male), 5-20 mg/day (female) / Split into 2 doses daily (morning and evening)
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Oxandrolone
HDL cholesterol suppression (dose-dependent, most significant lipid effect)
LDL cholesterol elevation
Mild hepatic stress (elevated liver enzymes ALT/AST)
Suppression of endogenous testosterone production
Mild headaches
Nausea or gastrointestinal discomfort
Changes in libido (increase or decrease depending on hormonal context)
Oily skin and mild acne
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Known or suspected prostate cancer
Breast cancer in males
Breast cancer with hypercalcemia in females
Pregnancy (Category X - known to cause fetal harm)
Nephrosis or nephrotic phase of nephritis
Hypercalcemia
Severe hepatic dysfunction or active liver disease
Hypersensitivity to oxandrolone or any formulation component
Research Evidence
CJC-1295 (without DAC) Oxandrolone
Status Well Studied Well Studied
References 5 studies 5 studies
Latest November 2024 September 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.